Ryo Takahashi1, Takahisa Fujikawa2. 1. Department of Surgery, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, Fukuoka, 8028555, Japan. 2. Department of Surgery, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, Fukuoka, 8028555, Japan. fujikawa-t@kokurakinen.or.jp.
Abstract
BACKGROUND: In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn. We investigated the safety of perioperative aspirin continuation, specifically focused on bleeding complications. METHODS: We performed retrospective analysis utilizing propensity score-matching (PSM). In total, 789 patients satisfied the inclusion criteria, and were divided into two groups. Patients in the continued aspirin monotherapy (cAPT) group continued treatment perioperatively with not more than 2 days of withdrawal (n = 140). Patients with more than 3 days withdrawal of aspirin or who did not receive APT at all were assigned to the non-cAPT group (n = 649). After 1:1 PSM, 105 patients were extracted from each group. Perioperative APT management was determined based on our institutional committee-approved guidelines for antithrombotic management. RESULTS: In PSM cohorts, all patient demographics were comparable between the groups. Regarding intraoperative outcomes, we found no significant difference in operation duration (p = 0.969), blood loss (p = 0.068), and blood transfusion (p = 0.517). Postoperative overall morbidity was 20.0% and 13.3% in the cAPT and non-cAPT groups, respectively (p = 0.195). The incidence of bleeding complications was also comparable between the groups (2.9% vs. 1.0%, p = 0.317). Assessing the 14 cases with bleeding complications overall in the full cohort, all 7 cases in the non-cAPT group had anastomotic bleeding, which was generally observed shortly after surgery [median postoperative day (POD) 1]. All 7 cases in the cAPT group received additional antithrombotics other than aspirin; bleeding occurred at various sites relatively later (median POD 7), mostly after reinstitution of additional antithrombotic agents. CONCLUSIONS: For patients receiving APT, perioperative continuation of aspirin monotherapy could be safe in laparoscopic CRC surgery; however, careful consideration is required at reinstitution of additional antithrombotics where multiple antithrombotic agents are used.
BACKGROUND: In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn. We investigated the safety of perioperative aspirin continuation, specifically focused on bleeding complications. METHODS: We performed retrospective analysis utilizing propensity score-matching (PSM). In total, 789 patients satisfied the inclusion criteria, and were divided into two groups. Patients in the continued aspirin monotherapy (cAPT) group continued treatment perioperatively with not more than 2 days of withdrawal (n = 140). Patients with more than 3 days withdrawal of aspirin or who did not receive APT at all were assigned to the non-cAPT group (n = 649). After 1:1 PSM, 105 patients were extracted from each group. Perioperative APT management was determined based on our institutional committee-approved guidelines for antithrombotic management. RESULTS: In PSM cohorts, all patient demographics were comparable between the groups. Regarding intraoperative outcomes, we found no significant difference in operation duration (p = 0.969), blood loss (p = 0.068), and blood transfusion (p = 0.517). Postoperative overall morbidity was 20.0% and 13.3% in the cAPT and non-cAPT groups, respectively (p = 0.195). The incidence of bleeding complications was also comparable between the groups (2.9% vs. 1.0%, p = 0.317). Assessing the 14 cases with bleeding complications overall in the full cohort, all 7 cases in the non-cAPT group had anastomotic bleeding, which was generally observed shortly after surgery [median postoperative day (POD) 1]. All 7 cases in the cAPT group received additional antithrombotics other than aspirin; bleeding occurred at various sites relatively later (median POD 7), mostly after reinstitution of additional antithrombotic agents. CONCLUSIONS: For patients receiving APT, perioperative continuation of aspirin monotherapy could be safe in laparoscopic CRC surgery; however, careful consideration is required at reinstitution of additional antithrombotics where multiple antithrombotic agents are used.
Authors: Ruben Veldkamp; Esther Kuhry; Wim C J Hop; J Jeekel; G Kazemier; H Jaap Bonjer; Eva Haglind; Lars Påhlman; Miguel A Cuesta; Simon Msika; Mario Morino; Antonio M Lacy Journal: Lancet Oncol Date: 2005-07 Impact factor: 41.316
Authors: Lee A Fleisher; Kirsten E Fleischmann; Andrew D Auerbach; Susan A Barnason; Joshua A Beckman; Biykem Bozkurt; Victor G Davila-Roman; Marie D Gerhard-Herman; Thomas A Holly; Garvan C Kane; Joseph E Marine; M Timothy Nelson; Crystal C Spencer; Annemarie Thompson; Henry H Ting; Barry F Uretsky; Duminda N Wijeysundera Journal: Circulation Date: 2014-08-01 Impact factor: 29.690
Authors: Steen Dalby Kristensen; Juhani Knuuti; Antti Saraste; Stefan Anker; Hans Erik Bøtker; Stefan De Hert; Ian Ford; Jose Ramón Gonzalez-Juanatey; Bulent Gorenek; Guy Robert Heyndrickx; Andreas Hoeft; Kurt Huber; Bernard Iung; Keld Per Kjeldsen; Dan Longrois; Thomas F Lüscher; Luc Pierard; Stuart Pocock; Susanna Price; Marco Roffi; Per Anton Sirnes; Miguel Sousa-Uva; Vasilis Voudris; Christian Funck-Brentano Journal: Eur Heart J Date: 2014-08-01 Impact factor: 29.983
Authors: J Mantz; C M Samama; F Tubach; P J Devereaux; J-P Collet; P Albaladejo; B Cholley; R Nizard; J Barré; V Piriou; N Poirier; A Mignon; S Schlumberger; D Longrois; F Aubrun; M E Farèse; P Ravaud; P G Steg Journal: Br J Anaesth Date: 2011-08-27 Impact factor: 9.166
Authors: P J Devereaux; Marko Mrkobrada; Daniel I Sessler; Kate Leslie; Pablo Alonso-Coello; Andrea Kurz; Juan Carlos Villar; Alben Sigamani; Bruce M Biccard; Christian S Meyhoff; Joel L Parlow; Gordon Guyatt; Andrea Robinson; Amit X Garg; Reitze N Rodseth; Fernando Botto; Giovanna Lurati Buse; Denis Xavier; Matthew T V Chan; Maria Tiboni; Deborah Cook; Priya A Kumar; Patrice Forget; German Malaga; Edith Fleischmann; Mohammed Amir; John Eikelboom; Richard Mizera; David Torres; C Y Wang; Tomas VanHelder; Pilar Paniagua; Otavio Berwanger; Sadeesh Srinathan; Michelle Graham; Laura Pasin; Yannick Le Manach; Peggy Gao; Janice Pogue; Richard Whitlock; André Lamy; Clive Kearon; Colin Baigent; Clara Chow; Shirley Pettit; Susan Chrolavicius; Salim Yusuf Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Mark Buunen; Ruben Veldkamp; Wim C J Hop; Esther Kuhry; Johannes Jeekel; Eva Haglind; Lars Påhlman; Miguel A Cuesta; Simon Msika; Mario Morino; Antonio Lacy; Hendrik J Bonjer Journal: Lancet Oncol Date: 2008-12-13 Impact factor: 41.316
Authors: Antonio M Lacy; Juan C García-Valdecasas; Salvadora Delgado; Antoni Castells; Pilar Taurá; Josep M Piqué; Josep Visa Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: James Fleshman; Daniel J Sargent; Erin Green; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; Heidi Nelson Journal: Ann Surg Date: 2007-10 Impact factor: 12.969